Guillem Casanovas

Guillem Casanovas

Auto-generated profile, based on publicly available information

Guillem Casanovas

Department of Pediatric Oncology, Hematology and Immunology, University Hospital of Heidelberg, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2009 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
GCGuillem Casanovas
Guillem Casanovas
KMKatarzyna Mleczko-Sanecka
Katarzyna Mleczko-Sanecka
SASandro Altamura
Sandro Altamura
MHMatthias W. Hentze
Matthias W. Hentze
MMMartina Ulrike Muckenthaler
Martina Ulrike Muckenthaler

18 April 2008 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
VFVerga Falzacappa
Verga Falzacappa
MVMaria Vittoria
Maria Vittoria
GCGuillem Casanovas
Guillem Casanovas
MHMatthias W. Hentze
Matthias W. Hentze
MMMartina Ulrike Muckenthaler
Martina Ulrike Muckenthaler

1 April 2010 in Blood
Verified
Journal Article
Closed access
KMKatarzyna Mleczko-Sanecka
Katarzyna Mleczko-Sanecka
GCGuillem Casanovas
Guillem Casanovas
ARAnan Ragab
Anan Ragab
KBKatja Breitkopf
Katja Breitkopf
AMAlexandra Müller
Alexandra Müller
MMMartina Ulrike Muckenthaler
Martina Ulrike Muckenthaler
Hepcidin is the master regulatory hormone of systemic iron metabolism. Hepcidin deficiency causes common iron overload syndromes whereas its overexpression is responsible for microcytic anemias. Hepcidin transcription is activated by the bone morphogenetic protein (BMP) and the inflammatory JAK-STAT pathways, whereas comparatively little is known about how hepcidin expression is inhibited. By using high-throughput siRNA screening we identified SMAD7 as a potent hepcidin suppressor. SMAD7 is an inhibitory SMAD protein that mediates a negative feedback loop to both transforming growth factor-β and BMP signaling and that recently was shown to be coregulated with hepcidin via SMAD4 in response to altered iron availability in vivo. We show that SMAD7 is coregulated with hepcidin by BMPs in primary murine hepatocytes and that SMAD7 overexpression completely abolishes hepcidin activation by BMPs and transforming growth factor-β. We identify a distinct SMAD regulatory motif (GTCAAGAC) within the hepcidin promoter involved in SMAD7-dependent hepcidin suppression, demonstrating that SMAD7 does not simply antagonize the previously reported hemojuvelin/BMP-responsive elements. This work identifies a potent inhibitory factor for hepcidin expression and uncovers a negative feedback pathway for hepcidin regulation, providing insight into a mechanism how hepcidin expression may be limited to avoid iron deficiency.

14 September 2012 in Haematologica
Verified
Journal Article
Closed access
GCG. Casanovas
G. Casanovas
MSM. V. Spasic
M. V. Spasic
CCC. Casu
C. Casu
SRS. Rivella
S. Rivella
JSJ. Strelau
J. Strelau
MMMartina Ulrike Muckenthaler
Martina Ulrike Muckenthaler
In conditions of increased erythropoiesis, expression of hepcidin, the master regulator of systemic iron homeostasis, is decreased to allow for the release of iron into the blood stream from duodenal enterocytes and macrophages. It has been suggested that hepcidin suppression is controlled by growth differentiation factor 15 (GDF15), a member of the transforming growth factor-β superfamily of cytokines that is secreted from developing erythroblasts. In this study, we analyzed iron-related parameters in mice deficient for GDF15 under steady-state conditions and in response to increased erythropoietic activity induced by blood loss. We demonstrate that GDF15 suppresses the hepatic mRNA expression of some BMP/TGFβ target genes but not of hepcidin, and show that GDF15 is not required to balance iron homeostasis in response to blood loss.

11 November 2016 in Circulation Research
Verified
Journal Article
Closed access
PDF file
JBJoyce Ellen Bischoff
Joyce Ellen Bischoff
GCGuillem Casanovas
Guillem Casanovas
JWJill Wylie-Sears
Jill Wylie-Sears
DKDae-Hee Kim
Dae-Hee Kim
PBPhilipp E. Bartko
Philipp E. Bartko
RLRobert A. Levine
Robert A. Levine
Rationale: : Ischemic mitral regurgitation, a complication after myocardial infarction (MI), induces adaptive mitral valve (MV) responses that may be initially beneficial but eventually lead to leaflet fibrosis and MV dysfunction. We sought to examine the MV endothelial response and its potential contribution to ischemic mitral regurgitation. Objective: : Endothelial, interstitial, and hematopoietic cells in MVs from post-MI sheep were quantified. MV endothelial CD45, found post MI, was analyzed in vitro. Methods and Results: : Ovine MVs, harvested 6 months after inferior MI, showed CD45, a protein tyrosine phosphatase, colocalized with von Willebrand factor, an endothelial marker. Flow cytometry of MV cells revealed significant increases in CD45 + endothelial cells (VE-cadherin + /CD45 + /α-smooth muscle actin [SMA] + and VE-cadherin + /CD45 + /αSMA− cells) and possible fibrocytes (VE-cadherin − /CD45 + /αSMA + ) in inferior MI compared with sham-operated and normal sheep. CD45 + cells correlated with MV fibrosis and mitral regurgitation severity. VE-cadherin + /CD45 + /αSMA + cells suggested that CD45 may be linked to endothelial-to-mesenchymal transition (EndMT). MV endothelial cells treated with transforming growth factor-β1 to induce EndMT expressed CD45 and fibrosis markers collagen 1 and 3 and transforming growth factor-β1 to 3, not observed in transforming growth factor-β1–treated arterial endothelial cells. A CD45 protein tyrosine phosphatase inhibitor blocked induction of EndMT and fibrosis markers and inhibited EndMT-associated migration of MV endothelial cells. Conclusions: : MV endothelial cells express CD45, both in vivo post MI and in vitro in response to transforming growth factor-β1. A CD45 phosphatase inhibitor blocked hallmarks of EndMT in MV endothelial cells. These results point to a novel, functional requirement for CD45 phosphatase activity in EndMT. The contribution of CD45 + endothelial cells to MV adaptation and fibrosis post MI warrants investigation.

1 October 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
GMGunda Millonig
Gunda Millonig
IGIngo Ganzleben
Ingo Ganzleben
TPTeresa Peccerella
Teresa Peccerella
GCGuillem Casanovas
Guillem Casanovas
LBLidia Brodziak-Jarosz
Lidia Brodziak-Jarosz
SMSebastian Mueller
Sebastian Mueller
The peptide hormone hepcidin regulates mammalian iron homeostasis by blocking ferroportin-mediated iron export from macrophages and the duodenum. During inflammation, hepcidin is strongly induced by interleukin 6, eventually leading to the anemia of chronic disease. Here we show that hepatoma cells and primary hepatocytes strongly up-regulate hepcidin when exposed to low concentrations of H2O2 (0.3–6 μm), concentrations that are comparable with levels of H2O2 released by inflammatory cells. In contrast, bolus treatment of H2O2 has no effect at low concentrations and even suppresses hepcidin at concentrations of >50 μm. H2O2 treatment synergistically stimulates hepcidin promoter activity in combination with recombinant interleukin-6 or bone morphogenetic protein-6 and in a manner that requires a functional STAT3-responsive element. The H2O2-mediated hepcidin induction requires STAT3 phosphorylation and is effectively blocked by siRNA-mediated STAT3 silencing, overexpression of SOCS3 (suppressor of cytokine signaling 3), and antioxidants such as N-acetylcysteine. Glycoprotein 130 (gp130) is required for H2O2 responsiveness, and Janus kinase 1 (JAK1) is required for adequate basal signaling, whereas Janus kinase 2 (JAK2) is dispensable upstream of STAT3. Importantly, hepcidin levels are also increased by intracellular H2O2 released from the respiratory chain in the presence of rotenone or antimycin A. Our results suggest a novel mechanism of hepcidin regulation by nanomolar levels of sustained H2O2. Thus, similar to cytokines, H2O2 provides an important regulatory link between inflammation and iron metabolism.